Royal Bank of Canada Reaffirms Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “outperform” rating reiterated by Royal Bank of Canada in a report issued on Monday, Benzinga reports. They presently have a $182.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s price target suggests a potential upside of 41.88% from the stock’s current price.

Several other equities research analysts also recently weighed in on SRPT. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Leerink Partners boosted their price objective on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, June 24th. Piper Sandler dropped their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, UBS Group boosted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $182.95.

Sarepta Therapeutics Trading Up 0.9 %

NASDAQ SRPT traded up $1.20 during mid-day trading on Monday, hitting $128.28. The company’s stock had a trading volume of 50,510 shares, compared to its average volume of 1,249,834. The firm has a market capitalization of $12.13 billion, a P/E ratio of 1,166.18 and a beta of 0.82. The stock’s fifty day simple moving average is $129.00 and its two-hundred day simple moving average is $132.36. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. The business’s revenue was up 38.9% compared to the same quarter last year. Research analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Riggs Asset Managment Co. Inc. grew its stake in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares in the last quarter. GAMMA Investing LLC raised its holdings in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the last quarter. EP Wealth Advisors LLC raised its holdings in Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Sarepta Therapeutics by 1.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after buying an additional 120 shares during the last quarter. Finally, Innealta Capital LLC bought a new position in Sarepta Therapeutics in the 2nd quarter worth $31,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.